Asset Details
Do you wish to reserve the book?
Pembrolizumab plus chemotherapy prolongs OS, PFS in metastatic lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pembrolizumab plus chemotherapy prolongs OS, PFS in metastatic lung cancer
Do you wish to request the book?
Pembrolizumab plus chemotherapy prolongs OS, PFS in metastatic lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pembrolizumab plus chemotherapy prolongs OS, PFS in metastatic lung cancer
2018
Overview
The addition of pembrolizumab to chemotherapy extended OS and PFS compared with chemotherapy alone among patients with metastatic squamous non-small cell lung cancer, according to results of the randomized phase 3 KEYNOTE-407 trial. Luis Paz-Ares, MD - chair of the department of medical oncology at Hospital Doce de Octubre, associate professor at Universidad Complutense, and head of the lung cancer unit at National Oncology Research Center in Madrid - and colleagues assigned patients to 200 mg pembrolizumab (Keytruda, Merck) or saline placebo on day 1 of each cycle for up to 35 cycles. A retrospective study revealed baseline steroid use of prednisone (> 10 mg) was associated with poorer outcomes (overall response rate, PFS and OS) among patients with NSCLC treated with PD-L1 blockade therapy.
Publisher
SLACK INCORPORATED
